Rivoceranib Medicine 10 December 2019 Extended indication Behandeling van vergevorderde of gemetastaseerd maagkanker 3L Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Rivoceranib Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Stomach cancer Extended indication Behandeling van vergevorderde of gemetastaseerd maagkanker 3L Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer LSK BioPharma Portfolio holder Mechanism of action Tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date 2020 Expected Registration 2021 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Fase 3 studie inmiddels afgerond. Therapeutic value Current treatment options Capecitabine, en in de toekomst trifluridine / tipiracil Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration References NCT03042611 Additional remarks Expected patient volume per year Patient volume < 78 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References IKNL; expertopinie Additional remarks Ongeveer 70 patiënten wordt behandeld in de 2e lijn voor gemetastaseerd adenocarcinoom van de maag of gastro-oesofageale overgang. Het aantal patiënten met een slokdarmcarcinoom die in de tweede lijn worden behandeld bedraagt ongeveer 60. In totaal zijn dit dus 130 patiënten. De inschatting is dat hiervan maximaal 60% een derde lijns behandeling krijgt (78 patiënten). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Liver cancer; Non-small cell lung cancer; Ovarian cancer References AdisInsight Additional remarks De verwachting is echter niet dat deze indicatieuitbreidingen binnen 2 jaar zullen plaatsvinden. Other information Additional remarks